Arcturus therapeutics receives orphan drug designation from the u.s. fda for arct-032, for the treatment of cystic fibrosis

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the u.s. food and drug administration (fda) has granted orphan drug designation for the company's product candidate arct-032 to treat cystic fibrosis (cf). the fda's office of orphan products dev.
ARCT Ratings Summary
ARCT Quant Ranking